Tianjin Pharmaceutical Da Ren Tang Group Corp - Stock

Tianjin Pharmaceutical Da Ren Tang Group Corp P/S 2024

Tianjin Pharmaceutical Da Ren Tang Group Corp P/S

2.99

Ticker

600329.SS

ISIN

CNE000001808

As of Jun 13, 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp's P/S ratio stood at 2.99, a -39.1% change from the 4.91 P/S ratio recorded in the previous year.

The Tianjin Pharmaceutical Da Ren Tang Group Corp P/S history

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktienanalyse

What does Tianjin Pharmaceutical Da Ren Tang Group Corp do?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is one of the leading pharmaceutical companies in China. It was founded in 1994 and is headquartered in the city of Tianjin in the northern part of the country. Zhongxin is a publicly traded company and employs over 6,000 employees. The business model of Zhongxin is diversified and includes manufacturing, research and development, sales, and marketing of pharmaceuticals and medical devices. The company strives to provide its customers with high-quality products and services and operates in various specialized areas. One of Zhongxin's main divisions is the manufacturing of pharmaceutical products. The company specializes in the production of cardiology, gastroenterology, oncology, and traditional Chinese medicines. Zhongxin operates multiple production facilities in China and has a productive R&D department focused on drug development. Another important part of Zhongxin's business is the distribution of its products. The company operates several distribution centers in China and is also increasing its presence in international markets. Distribution is done either directly to end customers or through intermediaries. In addition to the sale of medications, Zhongxin is also involved in medical wholesale activities, including retail and delivery of medical equipment and instruments. The company is capable of providing all types of medical devices and instruments from imaging and diagnostics to surgical instruments and implants. Zhongxin also has a specialized chemicals and raw materials division focused on the production of pharmaceutical active ingredients and intermediates. This gives the company additional control over the quality of its products as it is able to produce raw materials itself. The company is always seeking new innovations and heavily investing in research and development. In recent times, Zhongxin has invested in the development of biotech and nucleic acid therapies and intends to develop further innovative treatment methods. Zhongxin has also developed a strong presence in international markets in recent years. It has subsidiaries in several countries including the USA, Australia, Japan, and Europe. The company engages in joint ventures and strategic partnerships to enhance its raw material procurement and expand its reach internationally. Overall, Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a significant player in the pharmaceutical industry in China and on the international stage. The company has established a reputation as a reliable producer of high-quality medical products and services and continues to strive for success through innovation and expansion. Tianjin Pharmaceutical Da Ren Tang Group Corp ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Tianjin Pharmaceutical Da Ren Tang Group Corp's P/S Ratio

Tianjin Pharmaceutical Da Ren Tang Group Corp's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Tianjin Pharmaceutical Da Ren Tang Group Corp's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Tianjin Pharmaceutical Da Ren Tang Group Corp's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Tianjin Pharmaceutical Da Ren Tang Group Corp’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Tianjin Pharmaceutical Da Ren Tang Group Corp Stock

What is the price-to-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp is currently 2.99.

How has the price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp changed compared to last year?

The price-to-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp has increased by -39.1% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp high compared to other companies?

Yes, the price-to-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp is high compared to other companies.

How does an increase in the price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp affect the company?

An increase in the price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp affect the company?

A decrease in the price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp?

Some factors that influence the price-earnings ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Tianjin Pharmaceutical Da Ren Tang Group Corp pay?

Over the past 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp paid a dividend of 1.12 CNY . This corresponds to a dividend yield of about 3.06 %. For the coming 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp is expected to pay a dividend of 1.21 CNY.

What is the dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The current dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp is 3.06 %.

When does Tianjin Pharmaceutical Da Ren Tang Group Corp pay dividends?

Tianjin Pharmaceutical Da Ren Tang Group Corp pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Pharmaceutical Da Ren Tang Group Corp paid dividends every year for the past 16 years.

What is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

For the upcoming 12 months, dividends amounting to 1.21 CNY are expected. This corresponds to a dividend yield of 3.3 %.

In which sector is Tianjin Pharmaceutical Da Ren Tang Group Corp located?

Tianjin Pharmaceutical Da Ren Tang Group Corp is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tianjin Pharmaceutical Da Ren Tang Group Corp kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp from 6/6/2023 amounting to 1.12 CNY, you needed to have the stock in your portfolio before the ex-date on 6/6/2023.

When did Tianjin Pharmaceutical Da Ren Tang Group Corp pay the last dividend?

The last dividend was paid out on 6/6/2023.

What was the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp in the year 2023?

In the year 2023, Tianjin Pharmaceutical Da Ren Tang Group Corp distributed 0.5 CNY as dividends.

In which currency does Tianjin Pharmaceutical Da Ren Tang Group Corp pay out the dividend?

The dividends of Tianjin Pharmaceutical Da Ren Tang Group Corp are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.